These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18285443)

  • 1. Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective.
    Alonso A; Molenberghs G
    Stat Methods Med Res; 2008 Oct; 17(5):497-504. PubMed ID: 18285443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate marker evaluation from an information theory perspective.
    Alonso A; Molenberghs G
    Biometrics; 2007 Mar; 63(1):180-6. PubMed ID: 17447943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unifying approach for surrogate marker validation based on Prentice's criteria.
    Alonso A; Molenberghs G; Geys H; Buyse M; Vangeneugden T
    Stat Med; 2006 Jan; 25(2):205-21. PubMed ID: 16220497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative methods to evaluate trial level surrogacy.
    Abrahantes JC; Shkedy Z; Molenberghs G
    Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
    Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
    Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
    Renfro LA; Shi Q; Sargent DJ; Carlin BP
    Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints.
    Pryseley A; Tilahun A; Alonso A; Molenberghs G
    Clin Trials; 2007; 4(6):587-97. PubMed ID: 18042568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
    Piedbois P; Miller Croswell J
    Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials.
    Molenberghs G; Burzykowski T; Alonso A; Assam P; Tilahun A; Buyse M
    Stat Methods Med Res; 2010 Jun; 19(3):205-36. PubMed ID: 19608602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
    Baker SG
    Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Validation of surrogate endpoints in digestive oncology].
    Methy N; Bedenne L; Bonnetain F
    Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of the prentice criteria for surrogate endpoints.
    O'Quigley J; Flandre P
    Biometrics; 2006 Mar; 62(1):297-300. PubMed ID: 16542258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer.
    Hughes MD
    Stat Methods Med Res; 2008 Oct; 17(5):487-95. PubMed ID: 18285440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Information theory-based surrogate marker evaluation from several randomized clinical trials with binary endpoints, using SAS.
    Tilahun A; Pryseley A; Alonso A; Molenberghs G
    J Biopharm Stat; 2008; 18(2):326-41. PubMed ID: 18327724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
    Lassere MN; Johnson KR; Boers M; Tugwell P; Brooks P; Simon L; Strand V; Conaghan PG; Ostergaard M; Maksymowych WP; Landewe R; Bresnihan B; Tak PP; Wakefield R; Mease P; Bingham CO; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
    J Rheumatol; 2007 Mar; 34(3):607-15. PubMed ID: 17343307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
    Lassere MN
    Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical methodology of meta-analysis of individual patient data using a survival outcome.
    Katsahian S; Latouche A; Mary JY; Chevret S; Porcher R
    Contemp Clin Trials; 2008 Mar; 29(2):220-30. PubMed ID: 17884735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surrogate endpoint validation: statistical elegance versus clinical relevance.
    Green E; Yothers G; Sargent DJ
    Stat Methods Med Res; 2008 Oct; 17(5):477-86. PubMed ID: 18285438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.